MDA vs MDMA: The Difference Between Sally and Molly

MDA (“Sally”) and MDMA (“Molly”) differ by a single methyl group, and that is enough to make them behave like different drugs. MDA is more hallucinogenic and more visual, lasts roughly twice as long, and causes greater serotonin terminal damage than MDMA at equivalent doses in animal studies. You cannot tell them apart by looking, and Marquis cannot tell them apart either. Simon’s can.

One methyl group, two drugs

Both are substituted amphetamines in the methylenedioxy family. MDMA has an N-methyl group; MDA does not. That makes MDMA a secondary amine and MDA a primary amine, a distinction that turns out to matter for both how they feel and how you test them.

MDA came first. Both were synthesized in the early 20th century and both were investigated therapeutically before being controlled, and MDA was explored as an adjunct to psychotherapy in the 1960s and 70s, partly for its psychedelic character.

What MDA does that MDMA does not

Both drugs work mainly by reversing monoamine transporters, forcing serotonin, dopamine and norepinephrine out of nerve terminals rather than taking them back up. In that respect they are the same. The difference is what MDA does on top.

MDA has greater functional activity at 5-HT2A receptors, the same ones LSD and psilocybin act on. In animal models it produces more hallucinogen-like behavior, measured by the head-twitch response, a reliable proxy for 5-HT2A agonism. Binding studies find both compounds only weakly bind 5-HT2A in absolute terms, somewhere around 3,000 to 15,000 nM depending on stereoisomer and assay, but MDA’s greater functional activity there is what explains the stronger visual and perceptual effects people report.

At the serotonin transporter the two are comparable. A 1986 study comparing the enantiomers directly found similar serotonin-releasing potency, with one notable difference: N-methylation reduces MDMA’s dopamine-releasing potency relative to MDA. That extra dopaminergic push is where MDA’s more driven, stimulating character comes from.

Short version: MDA is more visual and more stimulating, MDMA is warmer and less hallucinogenic.

Twice as long, which changes the redose math

Controlled human pharmacokinetic work measuring MDA as an MDMA metabolite, the closest available data, puts MDA’s half-life at 10.6 to 12.3 hours against roughly 7 to 8 hours for MDMA. Taken directly as the parent drug, MDA’s active duration is generally reported at 8 to 12 hours, against MDMA’s 4 to 6.

That difference is not trivia. A second dose taken at a typical MDMA redosing interval, 90 to 120 minutes, lands while the first MDA dose is nowhere near cleared. Everything unwanted also lasts longer: cardiovascular strain, hyperthermia risk, jaw clenching. An MDA night is a full day commitment, and the usual advice against redosing MDMA applies here with more force.

Your body makes MDA out of MDMA

Take MDMA and roughly 3 to 5 percent of the dose is converted to MDA in the liver by N-demethylation. MDA shows up in your blood and urine whether or not you took any.

Two things follow. Every MDMA experience already includes some MDA exposure. And on a second dose, with CYP2D6 already inhibited, MDA concentrations climb disproportionately, which one controlled study documented directly with repeated dosing. That is one more reason redosing is not a linear addition of what you already took.

Neurotoxicity: what the animal data can and cannot say

Animal studies consistently show both compounds damage serotonergic nerve terminals, and that MDA does more damage than MDMA at the same dose. A 1988 immunocytochemical study comparing them head to head found both selectively ablated serotonin axons throughout the forebrain, with MDA producing the larger reduction in axon density. MDA’s neurotoxicity in the rodent brain was first characterized in 1985.

The dose caveat is the whole story here. Those studies used 20 mg/kg by subcutaneous injection, twice daily, for four days. Scaled to a 70 kg person that is roughly 230 mg per dose, injected, twice a day, for four consecutive days, against a typical single oral recreational dose of 80 to 120 mg. Injection also produces much higher peak plasma concentrations than swallowing something does. What this research establishes is a mechanism and a ranking, MDA at least as neurotoxic as MDMA. It does not establish that oral MDA at recreational doses does what it did to those rodents.

No controlled human study has assessed MDA neurotoxicity on its own. The human literature on MDMA is already tangled by heavy-user sampling bias and polydrug confounding, and for MDA there is no equivalent literature at all. The honest conclusion is conditional: if MDMA carries neurotoxic risk at sufficient doses, MDA carries at least as much and probably more.

Simon’s is the only way to tell

Marquis turns purple-black for both. It confirms you have something in the methylenedioxyamphetamine family and stops there.

Simon’s reacts specifically with secondary amines. MDMA is one, so it turns blue. MDA is a primary amine, so it produces no blue color change. Purple-black on Marquis with no blue on Simon’s means you are probably holding MDA.

The DanceSafe MDMA kit is built around that pairing: Marquis, the two-part Simon’s, and Froehde to confirm. Add fentanyl test strips separately, because no reagent detects fentanyl, and read them the right way round: one line is positive, two lines is negative, one strip per sample. Step-by-step technique is in our drug testing guide.

How often is it actually MDA?

A 25-year analysis of samples submitted to EcstasyData found only 48 percent contained pure MDMA, with 199 distinct adulterants identified across 4,719 samples. MDA turns up in a meaningful share of the rest.

Read that number carefully, though. People submit samples to EcstasyData when they already suspect something is off, so the adulteration rate in that dataset almost certainly overstates the supply at large. What it does establish is that “sold as MDMA” is not an identification, and that Simon’s settles the question in about a minute.

If you find you have MDA, treat it more like a psychedelic than an empathogen when you plan: longer, more visual, less predictable if you were expecting a roll. Thermoregulation needs attention for the whole duration, not just the first few hours.

For dosing, risks and the supplement protocol, see our MDMA harm reduction guide. For specific combinations, the interaction checker.

Sources

PMID 39437494 | PMID 2457659 | PMID 2871581 | PMID 24142203 | PMID 2880735 | PMID 18520604 | PMID 15228154 | PMID 15071716 | PMID 4023719 | PMID 10671903 | PMID 2443644